2004
DOI: 10.1038/sj.bmt.1704446
|View full text |Cite
|
Sign up to set email alerts
|

I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients

Abstract: Summary:A retrospective population pharmacokinetic (PPK) analysis was performed in 24 pediatric patients (PEDS) (0.45-16.7 years old) receiving i.v. busulfan/cyclophosphamide (i.v. Bu/Cy 4) regimen prior to allogeneic hematopoietic stem cell transplantation. I.V. Bu doses were given as a 2-hour infusion every 6 h over 4 days. Initial dosing of i.v. Bu was 1 mg/kg for children p4 years old and 0.8 mg/kg for patients 44 years old. Bu plasma concentrations at doses 1, 9 and 13 were analyzed through a multivariate… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
156
2

Year Published

2006
2006
2020
2020

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 126 publications
(160 citation statements)
references
References 32 publications
2
156
2
Order By: Relevance
“…BU is rare. 30 Our earlier small-scale study revealed high inter-and intrapatient consistency for i.v. BU pharmacokinetics.…”
Section: Discussionmentioning
confidence: 99%
“…BU is rare. 30 Our earlier small-scale study revealed high inter-and intrapatient consistency for i.v. BU pharmacokinetics.…”
Section: Discussionmentioning
confidence: 99%
“…7,[26][27][28] Dose targeting based on therapeutic drug monitoring (TDM) also seems to improve event-free survival and survival rates and in some studies VOD-free survival compared with conventional BU treatment. 18,29,30 Despite these improvements, inter-patient variability still exists and the percentage of patients reaching the target AUC after the first dose remains low.…”
Section: Discussionmentioning
confidence: 99%
“…[10][11][12] There have been several reports about intravenous busulfan pharmacokinetics, [10][11][12][13] with only a few applying population pharmacokinetic analysis. 13 We report here, the results of the population pharmacokinetic modeling of intravenous busulfan. The aim of this analysis was to characterize the pharmacokinetics of intravenous busulfan, including the IOV and covariate relationships in patients.…”
Section: Introductionmentioning
confidence: 99%